ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ETOPOPHOS
Prostate and other male cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ETOPOPHOS Rx

Generic Name and Formulations:
Etoposide (as phosphate) 100mg/vial; pwd for IV infusion after reconstitution and dilution.

Company:
Bristol-Myers Squibb

Therapeutic Use:

Indications for ETOPOPHOS:

Refractory testicular tumors after appropriate radiation, surgery, and other chemotherapy.

Adult:

See full labeling. Give by IV infusion over 5 to 210 minutes; use doses equivalent to those used for VePesid (eg, 50–100mg/m2 per day on Days 1 through 5 to 100mg/m2 per day on Days 1, 3, 5). Repeat course every 3–4 weeks after recovery (esp. myelosuppression). Toxicity unknown at doses >175mg/m2 per day. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): see full labeling. Consider dose modification if any myelosuppressive effect due to previous radiation, chemotherapy, or in combination with other drugs.

Children:

Not established.

Warnings/Precautions:

Monitor blood (esp. CBCs/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Embryo-fetal toxicity. Advise patients to use effective contraception during therapy and for at least 4 months (males) or 6 months (females) after last dose. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with levamisole, others that inhibit phosphatase activity. May be potentiated by cyclosporine. Antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid). May potentiate warfarin; monitor INR. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), asthenia, alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; infertility, others.

How Supplied:

Single-dose vials—1

Indications for ETOPOPHOS:

Small cell lung cancer.

Adult:

See full labeling. Give by IV infusion over 5 to 210 minutes; use doses equivalent to those used for VePesid (eg, 35mg/m2 per day for 4 days to 50mg/m2 per day for 5 days). Repeat course every 3–4 weeks after recovery (esp. myelosuppression). Toxicity unknown at doses >175mg/m2 per day. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): see full labeling. Consider dose modification if any myelosuppressive effect due to previous radiation, chemotherapy, or in combination with other drugs.

Children:

Not established.

Warnings/Precautions:

Monitor blood (esp. CBCs/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Embryo-fetal toxicity. Advise patients to use effective contraception during therapy and for at least 4 months (males) or 6 months (females) after last dose. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with levamisole, others that inhibit phosphatase activity. May be potentiated by cyclosporine. Antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid). May potentiate warfarin; monitor INR. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), asthenia, alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; infertility, others.

How Supplied:

Single-dose vials—1

Sign Up for Free e-newsletters